Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in ...

Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer ...

Joe DePinto, MBA, discusses some of the key challenges to equitable access to cell and gene therapies, especially in ...

Petros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed ...